Ernst Boehnlein is co-founder and CEO of Suamya since inception. He studied biology at the Ruprecht-Karls-University of Heidelberg and graduated in 1986. He received his post-doctoral training at Duke University Medical Center in Durham, NC. In 1989, he joined the Sandoz Research Institute in Vienna, Austria, as group leader. In 1993 he became Director at Sandoz Pharmaceuticals and transferred a gene therapy project to Palo Alto where he co-directed a Sandoz-sponsored joint research program with SyStemix, Inc. In 1997, he joined the Novartis Institute for Biomedical Research as Executive Director in the Department of Arthritis and Bone Metabolism. In 2001, he moved back to Europe. Since then he held senior management positions in start-up biotech companies in Düsseldorf, Göttingen and Munich. From 2008 until 2022, he was Managing Director at TET Systems in Heidelberg.

Andrea Aschenbrenner studied pharmaceutics at the University of Munich. She received her PhD in pharmaceutical chemistry from University of Würzburg in 1998 and an MSc in Drug Regulatory Affairs from the University of Bonn in 2009. Andrea held various positions of increasing responsibility at different pharmaceutical and biotech companies in Germany and Ireland. During this time, she gained wide experience from early research through to marketed products, with an emphasis on Project/Program Management and Business Development roles. She joined Sumaya Biotech in January 2022.

Richard Thomson Luque studied medicine at the University of Málaga. After graduating in 2001, he got an MSc in Tropical Medicine and International Health by the Autonomous University of Barcelona (UAB). He specialized as a clinical analyst at the Germans Trias i Pujol Hospital in Badalona (Barcelona) and obtained a PhD in Molecular Biology and Biomedicine by the Unicersity Complutense of Madrid (UCM). With a GSK OpenLab fellowship he joined ISGLOBAL in Barcelona as medical research fellow and worked at the Tropical Medicine Foundation in Manaus, Brazil. In 2014 he joined the University of South Florida in Tampa. In 2017 he moved to Germany and received a Marie Sklodowska Curie postdoctoral fellowship at the Centre for Infectious Diseases at Heidelberg University. He joined Sumaya-Biotech in 2021.

Michael Lanzer studied Biology at the University of Heidelberg. After his Diploma, he joined the laboratory of Prof. Hermann Bujard to work with him on mechanisms of gene regulation in bacteria. He was awarded a PhD degree in 1988 from Heidelberg University. From 1988 to 1993, Michael Lanzer worked as a postdoctoral fellow at Memorial Sloan-Kettering Cancer Center in New York under the supervision of Prof. Jeffrey Ravetch, where he studied gene regulation and chromosome organization in the human malaria parasite Plasmodium falciparum. At the end of 1993, Michael Lanzer moved to the University of Würzburg to establish his own research laboratory as a junior research group leader and in 1999 he was appointed full professor and head of the Parasitology Department at Heidelberg University. The focus of his research interest has remained P. falciparum and, in particular, mechanisms of drug resistance and virulence and drug development. Michael Lanzer has published more than 150 PubMed listed scientific articles. He has coordinated several research networks funded by the EU and the DFG and has won twice funding from the German Excellence Initiative for a graduate school in Biology. Michael Lanzer has further served as member on several ERC review panels. Since 2017, he is the vice-dean for PhD affairs at the Biology Faculty at Heidelberg University.